Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 17/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 10/20 | 0.62 |
| ▸ | NPY1R | P25929 | 10/20 | 0.62 |
| ▸ | NPY2R | P49146 | 7/20 | 0.62 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14479447 | 0.97 | NPY4R (0.63) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL14479416 | 0.92 | NPY4R (0.67) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL14479393 | 0.92 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL14479327 | 0.92 | NPY4R (0.62) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL17166398 | 0.87 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL17166418 | 0.86 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL17166409 | 0.86 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL17166415 | 0.86 | NPY4R (0.53) | NPY4RNPY5RNPY1RNPY2RNPBWR1 | |
| SCHEMBL14479325 | 0.86 | GRIA1 (0.54) | — | |
| SCHEMBL14479422 | 0.85 | NPY4R (0.57) | NPY4RNPY5RNPY1RNPY2RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9155795-B2 | CXCR4 receptor compounds | ANCHOR THERAPEUTICS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130005944-A1 | CXCR4 Receptor Compounds | ACER THERAPEUTICS INC. | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005944-A1 | CXCR4 Receptor Compounds | CXCL12, CXCR4, CCR5 | NPY4R 2868/4885NPY5R 3514/4885NPY1R 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.